Mr Joshua Kriesel, president and CEO, BioQuiddity
The agreement covers the territory of the European Union and certain other European countries.
Cipla intends to launch the CE Marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market later this year.
"Cipla is an excellent strategic partner for BioQuiddity and our pre-filled ready-to-use post-surgical pain product candidates," said Mr Joshua Kriesel president and CEO, BioQuiddity.
"Cipla's strong commercial record puts them in an outstanding position to detail OneDose ReadyfusOR's safety, sterility, and ease of use value proposition objectives," he further expressed.
The ready-to-use infusion systems are non-electric, ambulatory, and should enable seamless transition between sites of care.
"We are thrilled to be BioQuiddity's European commercial partner for this product", said Mr Frank Pieters, head, Cipla Europe. "Cipla believes that this post-surgical pain product candidate presents a unique opportunity to provide an easy-to-use, well-tolerated, and efficient regional anesthesia system that could increase savings for healthcare providers and patients."
